Mode
Text Size
Log in / Sign up
N/A N=51 Treatment

Clinical Performance of a New Implant System for Bone Conduction Hearing

Deafness; Sensoneural Single Sided · Conductive Hearing Loss · Mixed Hearing Loss

Enrolled (actual)
51
Serious AEs
3.9%
Results posted
Feb 2020
Primary outcome: Primary: Hearing Performance: Threshold Audiometry, Pure Tone Average of 4 Frequencies, PTA4, Unaided Versus OSIA System at 3 Months — -25.8 dB (Decibel) — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Osia System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cochlear
Primary completion
Oct 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Hearing Performance: Threshold Audiometry, Pure Tone Average of 4 Frequencies, PTA4, Unaided Versus OSIA System at 3 Months
-25.8 <0.0001 sig
PRIMARY
Adaptive Speech Recognition in Noise, Unaided Versus OSIA System at 3 Months.
-13.3 <0.0001 sig
SECONDARY
Hearing Performance: Threshold Audiometry, Pure Tone Average, PTA4, Unaided Versus OSIA System at 4 Weeks, 6 and 12 Months
-24.9; -27.9; -30.4 <0.0001 sig
SECONDARY
Hearing Performance: Threshold Audiometry Individual Frequences, Unaided Versus OSIA System at 4 Weeks, 3, 6 and 12 Months
-10.3; -23.3; -28.3; -26.4; -24.2; -23.8 <0.0001 sig
SECONDARY
Speech in Quiet at 50, 65 and 80 dB SPL, Unaided Versus OSIA System at 4 Weeks, 3, 6 and 12 Months
38.0; 59.8; 29.3; 40.1; 60.6; 31.8 <0.0001 sig
SECONDARY
Adaptive Speech Recognition in Noise, Unaided Versus OSIA System at 4 Weeks, 6 and 12 Months
-12.1; -13.7; -13.6 <0.0001 sig
SECONDARY
Abbreviated Profile of Hearing Aid Benefit (APHAB) at 3 and 12 Months
24.1; 29.4; 25.8; -2.2; 26.1; 24.0 <0.0001 sig
SECONDARY
Health Utility Index (HUI) at 3 and 12 Months
0.081; -0.006; 0.173; 0.033; -0.018; 0.000 0.026 sig
SECONDARY
Speech, Spatial and Qualities of Hearing Scale (SSQ) at 3 and 12 Months
2.57; 2.91; 2.85; 1.88; 2.69; 2.94 <0.0001 sig
SECONDARY
Hearing Performance: Threshold Audiometry PTA4, With Reference Device BP110
-3.16; -3.82; -5.72; -7.85 <0.0001 sig
SECONDARY
Hearing Performance: Threshold Audiometry Individual Frequences With Reference Device BP110
3.58; -2.22; -3.30; 0.42; -0.48; -2.62 0.025 sig
SECONDARY
Speech in Quiet at 50, 65 and 80 dB SPL, With Reference Device BP110
2.40; 6.65; 1.17; 5.17; 7.48; 1.77 0.51
SECONDARY
Adaptive Speech Recognition in Noise, With Reference Device BP110
-6.12; -7.19; -7.91; -7.54 <0.0001 sig
SECONDARY
Surgical Information: Time of Surgery
97.2
SECONDARY
Soft Tissue Thickness
6.00
SECONDARY
Soft Tissue Reduction
10; 41
SECONDARY
Bone Polishing/Removal at Implant Site
42; 9
SECONDARY
Type of Anaesthesia
51; 0
SECONDARY
Location of BI300 Implant
48.3; 40.0; 9.64; 54.4
SECONDARY
Incision Type
30; 1; 22
SECONDARY
Daily Usage Time of Sound Processor
10.7; 10.5; 10.6; 11.3
SECONDARY
Comfort
77.3; 80.8; 78.2; 80.9
SECONDARY
Magnet Choice
0; 1; 11; 13; 12; 8
SECONDARY
Softpad Use
1; 47; 4; 45; 0; 50

Summary

To study the initial experience with implanting and fitting the new Bone conduction system in patients with conductive, mixed or Single sided Sensorineural deafness.

Eligibility Criteria

Inclusion Criteria

  • Adult subjects (18 years or older)
  • Subject with conductive or mixed hearing loss in the ear to be implanted. Bone conduction thresholds with pure tone average (PTA4; mean of 0.5, 1, 2 and 4 kHz) of 55 dB HL.

OR Subject with single-sided sensorineural deafness who is a candidate for Baha surgery. Air conduction thresholds with a pure tone average PTA4 of 20 dB HL (mean of 0.5, 1, 2 and 3 kHz) in the good ear OR subject who is indicated for an AC CROS but-for some reason-cannot or will not use an AC CROS (Air Conduction-Contralateral Routing of Signal).

  • Signed informed consent
  • Previous experience from amplified sound though a non-surgical solution. (For example but not limited to Hearing aid, CROS device, Bone conductional hearing device on headband/ softband)

Exclusion Criteria

  • Uncontrolled diabetes as judged by the investigator.
  • Condition that could jeopardise osseointegration and/or wound healing (e.g. osteoporosis, psoriasis, long-term systemic use of corticosteroids) or condition that may have an impact on the outcome of the investigation as judged by the investigator.
  • Insufficient bone quality and quantity for implantation of a BI300 Implant.
  • Subject that has received radiotherapy in the area of implantation, or is planned for such radiotherapy during the study period
  • Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator
  • Unable to follow investigational procedures, e.g. to complete quality of life scales.
  • Participation in another clinical investigation with pharmaceutical and/or device.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03086135). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search